Scott T. Tagawa, M.D., M.S., spoke with OncLive about the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.
IMMU-132 is an anti–TROP-2 antibody-drug conjugate comprised of SN-38. Regarding safety, the agent is not as toxic compared with other antibody-drug conjugates, Tagawa explains.
In a phase I/II study, grade 3 neutropenia was observed in patients who received IMMU-132, but grade 1/2 diarrhea was one of the most common adverse events. Preliminary findings demonstrate a median progression-free survival of 8.1 months with 50% maturity, and a median overall survival of 10.8 months, with 79% of patients still alive.